Stock Analysis

Rhone Ma Holdings Berhad Full Year 2024 Earnings: EPS: RM0.056 (vs RM0.055 in FY 2023)

KLSE:RHONEMA
Source: Shutterstock

Rhone Ma Holdings Berhad (KLSE:RHONEMA) Full Year 2024 Results

Key Financial Results

  • Revenue: RM211.6m (up 4.3% from FY 2023).
  • Net income: RM12.3m (up 1.8% from FY 2023).
  • Profit margin: 5.8% (down from 6.0% in FY 2023). The decrease in margin was driven by higher expenses.
  • EPS: RM0.056 (up from RM0.055 in FY 2023).
earnings-and-revenue-history
KLSE:RHONEMA Earnings and Revenue History February 20th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rhone Ma Holdings Berhad's share price is broadly unchanged from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Rhone Ma Holdings Berhad that you need to take into consideration.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KLSE:RHONEMA

Rhone Ma Holdings Berhad

An investment holding company, engages in the manufacture, trading, marketing, and distribution of biotechnology and animal health products primarily in Malaysia.

Flawless balance sheet and good value.